Literature DB >> 2587137

Pulmonary function tests and fluid balance in neonates with chronic lung disease during dexamethasone treatment.

I M Gladstone1, R A Ehrenkranz, H C Jacobs.   

Abstract

Pulmonary function tests and fluid balance were measured serially during treatment with dexamethasone in seven ventilator-dependent, 14- to 27-day-old infants. The infants showed no improvement in respiratory status during the prior 5 days. Birth weights ranged from 540 to 900 g, with gestational ages of 24 to 26 weeks. The decision to treat the infants with dexamethasone was made by the clinical team. Pulmonary function tests were performed prior to the first dose and then every 12 hours until extubation. Significant differences were first seen after only 12 hours of treatment. Five infants were extubated within 48 hours of starting therapy. Before extubation at 48 hours, changes were found in dynamic compliance (74% increase), total pulmonary resistance by midvolume and regression methods (38% and 35% decreases, respectively), and expiratory time constant (49% increase), with P less than .01 in all cases. An increase in urine output was also observed in the first 12 hours. Improvements in chronic lung disease produced by dexamethasone are rapid and may result from dexamethasone-induced pulmonary fluid shifts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2587137

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

Review 1.  Dexamethasone therapy in chronic lung disease.

Authors:  S Sardesai; M Durand
Journal:  Indian J Pediatr       Date:  1996 Jan-Feb       Impact factor: 1.967

Review 2.  The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.

Authors:  P C Ng
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

3.  The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.

Authors:  A F Williams
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

Review 4.  Chronic lung disease of prematurity: are we too cautious with steroids?

Authors:  M Silverman
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

5.  Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years.

Authors:  Patricia A Nixon; Lisa K Washburn; Michael S Schechter; T Michael O'Shea
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

6.  Effect of dexamethasone on IL-2 and IL-3 production by mononuclear cells in neonates and adults.

Authors:  H Bessler; R Straussberg; N Gurary; D Aloni; L Sirota
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-11       Impact factor: 5.747

7.  Surfactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease.

Authors:  M R Ashton; A D Postle; D E Smith; M A Hall
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-09       Impact factor: 5.747

8.  Tumour necrosis factor in the bronchoalveolar secretions of infants with the respiratory distress syndrome and the effect of dexamethasone treatment.

Authors:  S H Murch; T T MacDonald; C B Wood; K L Costeloe
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

9.  Dexamethasone treatment during ventilator dependency: possible life threatening gastrointestinal complications.

Authors:  E A O'Neil; W J Chwals; M D O'Shea; C S Turner
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

10.  Catabolic effect of dexamethasone in the preterm baby.

Authors:  K G Brownlee; P C Ng; M J Henderson; M Smith; J H Green; P R Dear
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.